SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-092931
Filing Date
2023-12-05
Accepted
2023-12-05 08:01:03
Documents
5
Period of Report
2023-12-05

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea189521-6k_neurosense.htm 6-K 11611
2 PRESS RELEASE, DATED DECEMBER 4, 2023 ea189521ex99-1_neurosense.htm EX-99.1 10576
3 PRESS RELEASE, DATED DECEMBER 5, 2023 ea189521ex99-2_neurosense.htm EX-99.2 22236
4 GRAPHIC ex99-1_001.jpg GRAPHIC 28032
5 GRAPHIC ex99-2_001.jpg GRAPHIC 8414
  Complete submission text file 0001213900-23-092931.txt   95924
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 231465240
SIC: 2834 Pharmaceutical Preparations